NCT01193907View on ClinicalTrials.gov

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Typhoid Fever
Interventions
BIOLOGICAL

NVGH Vi-CRM197 12.5 mcg

1 dose of 0.5 mL

BIOLOGICAL

NVGH Vi-CRM197 5.0 mcg

1 dose of 0.5 mL

BIOLOGICAL

NVGH Vi-CRM197 1.25 mcg

1 dose of 0.5 mL

BIOLOGICAL

Vi-polysaccharide vaccine

1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide

Trial Locations (1)

2610

Center for the Evaluation of Vaccination (CEV), Antwerp

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT01193907 - Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) | Biotech Hunter | Biotech Hunter